The European Paediatric Clinical Trials Network conect4children : activities of the Belgium National Network and its progression by Degraeuwe, Eva et al.
THE EUROPEAN PAEDIATRIC CLINICAL TRIALS NETWORK CONECT4CHILDREN:
ACTIVITIES OF THE BELGIUM NATIONAL NETWORK AND ITS PROGRESSION
GE35 SUBJECT GROUP INTERNAL MEDICINE AND PAEDIATRICS - PAEDIATRIC NEPHROLOGY
Eva Degraeuwe1,2, Leen De Taeye1, Mark Turner3, Lieve Nuytinck1, Daphné Christiaens2, Simon Vanderschaeghe2, Elke Gasthuys1, Sevasti Karamaria1,2, 
Catherine Van Der Straeten1,2, Johan Vande Walle1,2 Affiliations:  (1) Ghent University, (2) Ghent University Hospital (3) University of Liverpool (UK)
• Belgium is the second country
in Europe to receive national
approval for the KD-CAAP
study.
• Five additional industry
studies have been included
within the c4c network in the
coming years.
Health, Innovation and Research
Institute of UZ Gent (HIRUZ) and
BPCRN are involved in the work
package of data management and
data coordination.
• Unique data standardization
database: CDISC approved
• Approved by a paediatric
expert group.
• Completed Governance
Toolkit: site specific Data
Management Plan (DMP).
BPCRN is also involved in the
workpackage for completing a
sustainable business model:
• Updating the European and
National Sustainable business
model
• A complete SWOT analysis








Paediatric drug development faces recurrent barriers such as fragmentation of the stakeholders and differences between research
conduct between sites and countries (1-3). Paediatric clinical trial networks have made many and unique advances over the last years
through the possibility of a pan-European network funded by the Innovative Medicines Initiative (IMI2). In Europe, the IMI2-funded
conect4children (c4c) initiative has promoted innovation and standardizationwithin all levels of paediatric drug development (1,4).
The Belgium Paediatric Clinical Research Network (BCPRN) with its headquarters localized in Ghent, plays an essential role in these
developments being involved in most of the work packages of this pan-European network (5). Having its predecessor, the federal funded
(FWO) SAFEPEDRUG (IWT-SBO 130033) the groundwork was laid for translational research for paediatric drug development in Belgium
(3,6). One of the finalities was the establishment of a paediatric clinical trial center, connected to the adult trial department D.R.U.G. at the
University Hospital Ghent (6).
.
TakeHomeMessage
The SBO-funded SAFEPEDRUG preclinical research has evolved into a clinical setting within
the pan-European network of c4c. Over the past 3 years, substantial developments and
progress has been made with the Belgium network activity by BPCRN. Platforms such as
c4c and I-ACT for Children are essential to achieve substantial improvement in
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